

TARGETED BIOPSY + WATS^{3D}
THE NEW STANDARD OF QUALITY CARE IN BARRETT'S ESOPHAGUS

Protecting your
patients from
Esophageal Cancer
is no longer random.

Breakthrough study: **WATS^{3D} vs**
SEATTLE RANDOM BIOPSY PROTOCOL

Increased Detection of Barrett's Esophagus-Associated Dysplasia and Neoplasia Using Wide Area Transepithelial Sampling in Conjunction with 4-Quadrant Forceps Biopsies: Final Results from a Multi-Center, Prospective, Randomized Trial.

STUDY DESIGN

14 major academic GI centers participated in a double-blind, randomized, crossover study in which 160 high-risk patients undergoing BE surveillance were subjected to both WATS^{3D} and Seattle Protocol 4-quadrant forceps biopsies every 1-2 cm.

Forceps biopsies (FB) were reviewed by a central pathologist, John Goldblum, MD at the Cleveland Clinic, and all WATS^{3D} samples were independently reviewed by Frank Fromowitz, MD at CDx Diagnostics. All cases of WATS^{3D} discovered HGD/EAC not found on forceps biopsy were then subjected to a second blinded independent review by two central Cleveland Clinic pathologists, requiring unanimous confirmation of the WATS^{3D} finding using standard pathologic criteria.

“These data demonstrate that the use of WATS^{3D} sharply increases the detection rates of the most serious forms of esophageal pre-cancer compared to even meticulously-performed random biopsy.”
— Prashanth R. Vennalaganti, MD,
lead author, University of Kansas, School of Medicine


STUDY RESULTS

Seattle Protocol FB detected 7 cases of HGD/EAC, 6 of which were also detected by WATS^{3D} with the remaining case reported by WATS^{3D} as IND/LGD. WATS^{3D} found an additional 23 cases of HGD/EAC not detected on FB (12 were reported by FB as IND/LGD, while 11 were reported by FB as NDBE only). **Conclusion: WATS^{3D} found 4.1x more HGD/EAC than Seattle Protocol random biopsies.**

Detection of HGD/EAC with WATS^{3D} compared with Seattle Protocol random 4-quadrant FB

SEATTLE PROTOCOL

7 cases of HGD/EAC detected



WATS^{3D}

29 cases of HGD/EAC detected

ABOUT WATS^{3D}

Using a specially designed brush biopsy instrument, WATS^{3D} enables endoscopists to easily obtain a wide area, full-thickness, transepithelial tissue sample in just a few minutes. WATS^{3D} labs then perform computer-assisted, 3D analysis of this large, complex, disaggregated tissue specimen by synthesizing up to 100 2-D optical slices into a single 3-D image for pathology review. In 7 previous clinical trials (2011-2015), adjunctive use of WATS^{3D} was found to significantly increase the detection rate of Barrett's Esophagus and dysplasia/carcinoma when compared to the standard biopsy protocol alone.

For more information, please visit: www.wats3d.com or contact: 1-866-363-6239.

WATS^{3D}
CDx[®] Diagnostics

Breakthrough data:

WATS^{3D} is 4x more effective in detecting HGD/EAC than the Seattle Random Biopsy Protocol.